ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Case Report   
  • J Clin Exp Pathol,

Dramatic Response to Hormone Therapy Plus CDK4/6 Inhibitor of a Retinal Detachment Secondary to Luminal Advanced Breast Cancer

Martín Núñez-Abad1, Miguel Ortiz Salvador2, Silvia Calabuig-Fariñas3, Javier Montero Hernández2, Verónica Castro Navarro2, Vega Iranzo González-Cruz1* and Carlos Camps Herrero1
1Department of Medical Oncology, University General Hospital of Valencia, Valencia, Spain
2Department of Ophthalmology, Consorci Hospital General Universitari de Valencia, Valencia, Spain
3Department of Pathology, Universitat de València, Valencia, Spain
*Corresponding Author : Vega Iranzo González-Cruz, Department of Medical Oncology, University General Hospital of Valencia, Valencia, Spain

Received Date: Apr 23, 2021 / Accepted Date: May 07, 2021 / Published Date: May 14, 2021

Abstract

Luminal breast cancer is hormone-receptor positive (estrogen-receptor and/or progesterone-receptor positive) and human epidermal growth factor receptor 2-negative (HER2-). Currently, the standard treatment of luminal metastatic breast cancer is the combination of hormone therapy with CDK4/6 (Cyclin-Dependent Kinases 4/6) inhibitors. The overall response rates for the combination are between 40% to 50%, increasing Progression Free Survival (PFS) and Overall Survival (OS) compared with hormone therapy alone. Herein, we report a clinical case showing the management of a patient with luminal breast cancer in different stages of the disease, highlighting the dramatic response of cyclin inhibitor plus fulvestrant to a bilateral retinal detachment due to ocular metastases.

Keywords: Luminal breast cancer, Hormone Therapy, CDK4/6 inhibitor, Carcinoma, Meningioma

Citation: Abad MN, Salvador MO, Fariñas SC, Hernández JM, Navarro VC et al. (2021) Dramatic Response to Hormone Therapy Plus CDK4/6 Inhibitor of a Retinal Detachment Secondary to Luminal Advanced Breast Cancer. J Clin Exp Pathol 11: 399.

Copyright: © 2021 Abad MN, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top